Head-to-head evidence
Pralsetinib vs TAS0953
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: RET · full Non-Small Cell Lung Cancer pipeline
Pralsetinib
Marketed by Rigel Pharmaceuticals and partners
NCT04222972 · Phase 3 · terminated
This was a randomized, active-controlled trial in 223 patients that met its primary progression-free-survival endpoint with a clear statistical result, but it was conducted open-label (patients and investigators knew which treatment was given), which limits confidence in an investigator-assessed endpoint like progression.
Next expected readout: November 2026 · NCT04302025 (registry estimate)
TAS0953
Developed by Taiho Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2030 · NCT04683250 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pralsetinib's landscape · TAS0953's landscape